Lyell Immunopharma, Inc. Contracts & Agreements
40 Contracts & Agreements
- Business Finance (5 contracts)
- Business Operations (4)
- Human Resources (13)
- Intellectual Property (1)
- Real Estate (5)
- Uncategorized (12)
- Lyell Immunopharma, Inc. Non-Employee Director Compensation Policy (Filed With SEC on August 7, 2024)
- Offer Letter by and between the Registrant and Gary Lee, dated November 24, 2021 (Filed With SEC on February 28, 2024)
- Non-Employee Director Compensation Policy (Filed With SEC on November 7, 2023)
- Offer Letter by and between the Registrant and Matthew Lang, dated May 12, 2023 (Filed With SEC on November 7, 2023)
- Release and Separation Agreement (Filed With SEC on August 8, 2023)
- Description of Securities (Filed With SEC on February 28, 2023)
- Offer Letter, by and between Lynn Seely and Lyell Immunopharma, Inc., dated December 14, 2022 (Filed With SEC on December 16, 2022)
- Separation, Transition and General Release Agreement, by and between Elizabeth Homans and Lyell Immunopharma, Inc., dated December 15, 2022 (Filed With SEC on December 16, 2022)
- Offer Letter by and between the Registrant and Rahsaan (Filed With SEC on November 8, 2022)
- Notice and Acceptance of Amendment to Stock Options between the Registrant and Elizabeth Homans, dated (Filed With SEC on August 4, 2022)
- Severance Waiver by and between the Registrant and Stephen Hill, dated April 19, 2022 (Filed With SEC on May 10, 2022)
- Second Amendment to the Collaboration and License Agreement between the Registrant, GlaxoSmithKline Intellectual Property (No.5) Limited and Glaxo Group Limited, dated December... (Filed With SEC on March 29, 2022)
- Lyell Immunopharma, Inc. Officer Severance Plan (Filed With SEC on March 29, 2022)
- Form of Common Stock Certificate (Filed With SEC on June 9, 2021)
- Collaboration and License Agreement by and between the Registrant, GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited, dated May 23, 2019, as amended (Filed With SEC on June 9, 2021)
- Lyell Immunopharma, Inc. 2021 Non-Employee Director Compensation Policy (Filed With SEC on June 9, 2021)
- Lyell Immunopharma, Inc. 2021 Employee Stock Purchase Plan (Filed With SEC on June 9, 2021)
- Forms of Restricted Stock Unit Grant Notice and Award Agreement under the Lyell Immunopharma, Inc. 2021 Equity Incentive Plan (Filed With SEC on June 9, 2021)
- Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Lyell Immunopharma, Inc. 2021 Equity Incentive Plan (Filed With SEC on June 9, 2021)
- Lyell Immunopharma, Inc. 2021 Equity Incentive Plan (Filed With SEC on June 9, 2021)
- Form of Underwriting Agreement (Filed With SEC on June 9, 2021)
- Lyell Immunopharma, Inc. 2018 Equity Incentive Plan, as amended (Filed With SEC on May 25, 2021)
- Amended and Restated Investors Rights Agreement, by and among the Registrant and certain of its stockholders, dated March 5, 2020 (Filed With SEC on May 25, 2021)
- Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise and Restricted Stock Award Agreement under the Lyell Immunopharma, Inc. 2018 Equity Incentive Plan (Filed With SEC on May 25, 2021)
- Lyell Immunopharma, Inc. Officer Severance Plan (Filed With SEC on May 25, 2021)
- Form of Indemnification Agreement by and between the Registrant and its directors and executive officers (Filed With SEC on May 25, 2021)
- Amended Offer Letter by and between the Registrant and Richard Klausner, dated July 23, 2020 (Filed With SEC on May 25, 2021)
- Amended Offer Letter by and between the Registrant and Elizabeth Homans, dated July 23, 2020 (Filed With SEC on May 25, 2021)
- Offer Letter by and between the Registrant and Charles Newton, dated February 3, 2021 (Filed With SEC on May 25, 2021)
- Offer Letter by and between the Registrant and Heather Turner, dated February 1, 2019 (Filed With SEC on May 25, 2021)
- Offer Letter by and between the Registrant and Stephen Hill, dated May 9, 2019 (Filed With SEC on May 25, 2021)
- Collaboration and License Agreement by and between the Registrant, GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited, dated May 23, 2019, as amended (Filed With SEC on May 25, 2021)
- License Agreement by and between the Registrant and The Board of Trustees of the Leland Stanford Junior University, dated January 29, 2019 (Filed With SEC on May 25, 2021)
- Success Payment Agreement, by and between the Registrant and The Board of Trustees of the Leland Stanford Junior University, dated October 1, 2020 (Filed With SEC on May 25, 2021)
- Success Payment Agreement, by and between the Registrant and Fred Hutchinson Cancer Research Center, dated December 19, 2018 (Filed With SEC on May 25, 2021)
- Standard Office Lease for Building C by and between the Registrant and Bre Wa Office Owner LLC, dated August 28, 2019 (Filed With SEC on May 25, 2021)
- Standard Office Lease for Building E by and between the Registrant and Bre Wa Office Owner LLC, dated August 28, 2019 (Filed With SEC on May 25, 2021)
- Lease by and between the Registrant and BMR-500 Fairview Avenue LLC, dated November 27, 2018, as amended (Filed With SEC on May 25, 2021)
- Lease Agreement by and between the Registrant and ARE-San Francisco No. 65, LLC, dated August 15, 2019, as amended (Filed With SEC on May 25, 2021)
- Lease Agreement by and between the Registrant and ARE-East Jamie Court, LLC, dated January 14, 2019, as amended (Filed With SEC on May 25, 2021)
